The biopharmaceutical contract manufacturing market is projected to grow at a CAGR of 10% during 2022-2035, claims Roots Analysis
With the advent of novel technologies and rising preference for such therapeutic interventions, biologics have made a significant impact in the pharmaceutical domain, delivering a ground-breaking treatment regimen for a myriad of disease indications.
In pursuit of both time and cost savings, as well as to access higher scales of production, outsourcing has emerged as a lucrative option for biologic drug developers. Driven by several blockbuster products, a burgeoning pipeline of biologic drugs, the demand for reliable contract service providers, which have the required expertise and advanced manufacturing capabilities, is expected to grow at a commendable pace in the coming years. Currently over 275 companies claim to be biopharma CDMO / biopharma CMO, in compliance with the regulatory standards.
For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen
